Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection
ConditionOsteoarthritis of the Knee
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorRush University Medical Center
About this trial
Prospective single-masked (study participant will be masked), randomized controlled trial to examine the influence of BMAC on patient-reported outcomes (PROs) in patients with primary knee osteoarthritis.
Eligibility criteria
Qualifiers
Patients between the ages of 18-70
Long standing knee pain from osteoarthritis (KL grade 2-3) despite conventional treatments such as activity modification, weight loss, physical therapy, analgesics, nonsteroidal anti-inflammatory drugs, or injection therapy for at least 6 weeks
7-day average pain score of at least 4 on VAS scale
Disqualifiers
Systemic diseases (Diabetes, malignancies, infections, etc.)
Post-traumatic arthritis
Patient had intra-articular injection on affected knee in last three months
Trial design
Treatments tested in this trial
- Autologous bone marrow aspirate concentrate (BMAC)
- Corticosteroid injections
- Crossover Autologous bone marrow aspirate concentrate (BMAC)
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov